Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

GLP-1 weight-loss drugs such as Ozempic and Wegovy are driving down grocery spending, according to a new study from Cornell’s ...

A study in pigs has shown that the active ingredient in Ozempic and Wegovy directly boosts heart health, in addition to the ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

They are so effective, in one trial, patients who took the highest dose of Wegovy, which is only prescribed for weight loss, ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

(AP Photo/Manuel Balce Ceneta) WASHINGTON — Millions of Americans with obesity would be eligible to have popular weight-loss ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Ozempic and Wegovy, used for diabetes and weight loss, show a link to NAION, a rare eye disorder causing blindness. A study ...